Abstract 1033
Background
Soft tissue sarcomas are a rare subgroup in adults and children with oncological diseases. Since the 1970s, after the introduction of doxorubicin as a chemotherapeutic agent for the treatment of soft tissue sarcoma, the treatment of metastatic and primary localized sarcoma has remained weak, although several new therapeutic agents have been identified in this time. Participating in clinical trials can help solve this problem in general and particularly in countries with a low level of access to innovative medicines. We performed qualitative and quantitative comparative analysis of clinical trials for soft tissue sarcoma patients in Western and Eastern Europe.
Methods
Based on data from https://clinicaltrials.gov/ we searched for clinical trials that have been performed in 2009-2019 in 30 European countries (10 in Western and 20 in Eastern countries). Clinical trials by phases, type of therapy, soft tissue sarcoma type, stage of disease and status were studied.
Results
The vast majority of soft tissue sarcoma trials have been performed in Western Europe (401/467) and of those 212/52.9% of were phase II; average number of trials per country was 40, ranging from 30 (Switzerland) to 92 (France). In Eastern Europe the average number of trials per country was 3 with a maximum of 23 (Poland); 45.5% of trials were phase III. Clinical trials in adults (> 18 years) in Eastern Europe and Western Europe (78.8% vs 75.3%), in patients younger than 18 years (21.2% vs 24.7%), respectively. For soft tissue sarcoma stages I-II, III, (unresectable)/IV 1.0, 17.5 and 81.5% trials, respectively, have been held in Western Europe, 0, 18.2 and 81.8% trials in Eastern Europe. The most frequent clinical trials studies of targeted therapy, chemotherapy and combination treatment, constituting 35.9%, 20.4% and 17.2% trials in Western Europe and in 18.2%, 27.3% and 16.7% trials in Eastern Europe, respectively. Only 14.1% of trials are currently recruiting patients in Eastern Europe while 85.9% of recruitment is in Western Europe.
Conclusions
Access to clinical trials for soft tissue sarcoma patients in Western and Eastern Europe is quite different. Participation in clinical trials could help as patients from countries with low access to innovative medicines or oncologists could get necessary experience.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3690 - PD-L1 expression in resected undifferentiated pleomorphic sarcoma and its clinical implications
Presenter: Kyoungmin Lee
Session: Poster Display session 1
Resources:
Abstract
2013 - PD-L1 expression as a potential therapeutic target and prognostic biomarker in well-differentiated and dedifferentiated liposarcoma.
Presenter: Heejung Chae
Session: Poster Display session 1
Resources:
Abstract
5021 - Soft tissue sarcomas express a distinct mRNA immune profile
Presenter: Viktor Grünwald
Session: Poster Display session 1
Resources:
Abstract
3029 - The molecular landscape of fusion genes in endometrial stromal sarcomas include three nosological entities with different natural history
Presenter: Mehdi Brahmi
Session: Poster Display session 1
Resources:
Abstract
3914 - Clinical validation of a novel assay for the detection of diagnostic alterations in sarcomas
Presenter: Lauren Mc Connell
Session: Poster Display session 1
Resources:
Abstract
1912 - A prospective correlative trial of personalized patient-derived xenograft (PDX) as avatars for drug therapy in patients with metastatic or recurrent soft tissue sarcomas (STS).
Presenter: Kanan Alshammari
Session: Poster Display session 1
Resources:
Abstract
5097 - Fusion of immortalized myoblasts induces genomic instability that drives tumor development and progression.
Presenter: Candice Merle
Session: Poster Display session 1
Resources:
Abstract
1383 - let-7a suppress Ewing sarcoma CSCs' malignant phenotype through forms a positive feedback regulation loop with lin28 via STAT3
Presenter: Xu Jiang
Session: Poster Display session 1
Resources:
Abstract
3386 - Myoepithelial Tumors of Soft Tissues and Extraskeletal Myxoid Chondrosarcomas feature a distinct transcriptional pattern
Presenter: Dominga Racanelli
Session: Poster Display session 1
Resources:
Abstract
1844 - In Vivo Efficacy and Enhanced Tumor Accumulation of Liposomal Vinorelbine (TLC178) in Human Sarcoma Xenograft Mice Model
Presenter: Wan-ni Yu
Session: Poster Display session 1
Resources:
Abstract